Op-T is a clinical stage company based in Denver, Colorado that has developed a new therapeutic for controlling inflammation in autoimmune diseases, acute inflammatory conditions and certain chronic conditions across multiple species.

The company has received IND approvals from the FDA for Phase 1 studies in humans with type 1 diabetes (T1D) and in healthy humans toward later studies in Covid-19 patient populations. Op-T has also received INAD approval from the FDA’s Center for Veterinary Medicine (CVM) for a study to treat Diabetes mellitus (DM) in dogs.